Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)

【24h】

Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)

机译：生物意大利 - 生物标志物分析核细胞和Letrozole治疗的患者液体活组织检查分析，作为先进乳腺癌（ABC）的一线治疗（NCT03439046）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共4页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词
入库时间 2022-08-20 01:55:52

相似文献

外文文献
中文文献
专利

1. Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：生物意大利 - 生物标志物分析核细胞和Letrozole治疗的患者液体活组织检查分析，作为先进乳腺癌（ABC）的一线治疗（NCT03439046）
2. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy [J] . ZhaoH.-Y., HuangH., HuZ.-H., Anti-cancer drugs . 2012,第5期

机译：对以卡培他滨为基础的一线化疗治疗的复发/晚期乳腺癌患者对5-氟尿嘧啶和紫杉烷类药物敏感性相关的生物标志物评估
3. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies [J] . Cazzaniga M.E., Verusio C., Ciccarese M., Breast care . 2020,第1期

机译：在人力资源+ /海拔乳腺癌患者中仍然存在单独治疗的作用吗？在实际环境中分析高剂量氟斯特提治疗患者两种数据集的结果：EVA和GIM-13 AMBRA研究
4. Droplet-Scale Extraction of Biomarkers in Tissue Biopsies of Patients undergoing Breast Cancer Therapy by Digital Microfluidics and LC-MS. [C] . Johannes A Hewel, Nelson Lafreniere, Michael Watson, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2012

机译：数字微流体和LC-MS乳腺癌治疗患者组织活检生物标志物的液滴尺度提取。
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies [O] . Marina Elena Cazzaniga, Claudio Verusio, Mariangela Ciccarese, 2020

机译：在人力资源+ /海拔乳腺癌患者中仍然存在单独治疗的作用吗？在实际环境中分析高剂量氟斯特提治疗患者两种数据集的结果：EVA和GIM-13 AMBRA研究
7. Pooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC) [O] . D. Tripathy, G.N. Hortobagyi, A. Chan, 2019

机译：第一线核核苷酸（肋骨）加上内分泌治疗（ET）的汇总安全分析（ET）在HR + / HER2晚期乳腺癌（ABC）

Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)

著录项

相似文献

相关主题

期刊订阅